- ArthroMax® with Theaflavins & AprèsFlex®
- 120 vegetarian capsules
- Item Catalog Number: 01617
As you grow older, age-related stiffness and discomfort in the joints becomes a fact of life. Activities once routine become a challenge as limited mobility hampers your every move.
Inflammatory reactions are regulated by a series of "cytokines" produced in the body. Normal aging results in an unfavorable balance of these cytokines that contributes to persistent inflammatory conditions. Studies have shown that a special fraction found in black tea suppresses proinflammatory cytokines at the genomic level. Scientists have found that these compounds called theaflavins uniquely downregulate the expression of genes associated with inflammatory cytokines.72
ArthroMax® with Theaflavins & AprèsFlex® provides bioactive theaflavin fractions, along with MSM(methylsulfonylmethane), which contains sulfur components that are critically important in maintaining comfortable joint function.73-75 It also contains FruiteX B® OsteoBoron®, a patented form of boron identical to natural plant forms found in food. Considered more bioavailable than other forms of boron, FruiteX B® OsteoBoron® also supports healthy bones and joints.76-78
AprèsFlex® represents a quantum leap forward in the delivery of boswellia to aging joints. Long prized for its ability to help inhibit inflammatory factors, boswellia is especially effective at inhibiting the 5-LOX (5-lipoxygenase) enzyme.
Excess activity of 5-LOX results in the accumulation of leukotriene B4, a pro-inflammatory compound that affects aging joints. Boswellia has been shown to bind directly to the 5-LOX enzyme, preventing it from facilitating production of pro-inflammatory leukotrienes.69,70
AprèsFlex® boswellia absorbs into the blood 52% better than previously available forms of boswellia, for superior effectiveness.71
Not available for sale to Grocery and Drug Stores.
AprèsFlex® is a registered trademark of Laila Nutraceuticals exclusively licensed to PL Thomas – Laila Nutra LLC. U.S. Patent No. 8,551,496 and other patents pending.
|Dosage and Use|
To report a serious adverse event or obtain product information, contact1-866-280-2852.